UK separations company Whatman aims to double FTA sales in three years
This article was originally published in Clinica
Executive Summary
Whatman, the UK separations technology group, is aiming to double revenues from its FTA DNA collection, storage and purification cards in three years. CEO Bill Emhiser told Clinica that FTA sales should reach £16m ($30m) by the end of 2009, as markets such as forensics, pharmacogenomics testing in clinical trials, basic research and ultimately molecular diagnostics expand.